| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
National Public Health Institute and MediCity Research Laboratory, Turku University, Turku, Finland;
Liver Research Laboratories, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom; and
Department of Internal Medicine, Turku University Central Hospital, Turku, Finland
Vascular adhesion protein-1 (VAP-1) is a dimeric 170-kDa
endothelial transmembrane molecule that under normal conditions is most
strongly expressed on the high endothelial venules of peripheral lymph
nodes and on hepatic endothelia. It is a glycoprotein that mediates
tissue-selective lymphocyte adhesion in a sialic acid-dependent manner.
In this study, we report the detection of a soluble form of VAP-1 in
circulation. We developed a quantitative sandwich ELISA using novel
anti-VAP-1 mAbs and used it to determine the levels of soluble
VAP-1 (sVAP-1) in the serum of healthy individuals and in patients with
inflammatory diseases. In healthy persons, circulating sVAP-1
concentrations were 49 to 138 ng/ml. Immunoblotting studies revealed
that the apparent molecular mass of dimeric sVAP-1 is slightly
(
10 kDa) higher than that of transmembrane VAP-1 under nonreducing
conditions. In contrast, the electrophoretic mobilities of monomeric
sVAP-1 and transmembrane VAP-1 were similar after reduction and
boiling. Adhesion assays showed that the circulating sVAP-1 modulates
lymphocyte binding to endothelial cells. Inflammation can cause an
elevation of serum sVAP-1 levels, because sVAP-1 concentrations in
patients with certain liver diseases were two- to fourfold higher than
those in normal individuals. In contrast, rheumatoid arthritis and
inflammatory bowel diseases were not associated with elevated levels of
sVAP-1. These findings indicate that there is a functionally active,
soluble form of VAP-1 in circulation and suggest that the serum level
of sVAP-1 might be a useful marker of disease activity in inflammatory
liver diseases.
This article has been cited by other articles:
|
|
 |
|
  S. Jalkanen and M. Salmi VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 18 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hernandez-Guillamon, I. Bolea, M. Sole, M. Boada, K.F. Tipton, and M. Unzeta Sodium Bicarbonate Enhances Membrane-bound and Soluble Human Semicarbazide-sensitive Amine Oxidase Activity In Vitro J. Biochem., November 1, 2007; 142(5): 571 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salmi and S. Jalkanen Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans Blood, September 1, 2006; 108(5): 1555 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lautamaki, R. Borra, P. Iozzo, M. Komu, T. Lehtimaki, M. Salmi, S. Jalkanen, K. E. J. Airaksinen, J. Knuuti, R. Parkkola, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E282 - E290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Martelius, V. Salaspuro, M. Salmi, L. Krogerus, K. Hockerstedt, S. Jalkanen, and I. Lautenschlager Blockade of Vascular Adhesion Protein-1 Inhibits Lymphocyte Infiltration in Rat Liver Allograft Rejection Am. J. Pathol., December 1, 2004; 165(6): 1993 - 2001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Stolen, G. G. Yegutkin, R. Kurkijarvi, P. Bono, K. Alitalo, and S. Jalkanen Origins of Serum Semicarbazide-Sensitive Amine Oxidase Circ. Res., July 9, 2004; 95(1): 50 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vega, P. Chacon, J. Monteseirin, R. El Bekay, M. Alvarez, G. Alba, J. Conde, J. Martin-Nieto, F. J. Bedoya, E. Pintado, et al. A new role for monoamine oxidases in the modulation of macrophage-inducible nitric oxide synthase gene expression J. Leukoc. Biol., June 1, 2004; 75(6): 1093 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Koskinen, P. J. Vainio, D. J. Smith, M. Pihlavisto, S. Yla-Herttuala, S. Jalkanen, and M. Salmi Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1) Blood, May 1, 2004; 103(9): 3388 - 3395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gokturk, J. Nilsson, J. Nordquist, M. Kristensson, K. Svensson, C. Soderberg, M. Israelson, H. Garpenstrand, M. Sjoquist, L. Oreland, et al. Overexpression of Semicarbazide-Sensitive Amine Oxidase in Smooth Muscle Cells Leads to an Abnormal Structure of the Aortic Elastic Laminas Am. J. Pathol., November 1, 2003; 163(5): 1921 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Salmi, C. Stolen, P. Jousilahti, G. G. Yegutkin, P. Tapanainen, T. Janatuinen, M. Knip, S. Jalkanen, and V. Salomaa Insulin-Regulated Increase of Soluble Vascular Adhesion Protein-1 in Diabetes Am. J. Pathol., December 1, 2002; 161(6): 2255 - 2262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Lalor, S. Edwards, G. McNab, M. Salmi, S. Jalkanen, and D. H. Adams Vascular Adhesion Protein-1 Mediates Adhesion and Transmigration of Lymphocytes on Human Hepatic Endothelial Cells J. Immunol., July 15, 2002; 169(2): 983 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Irjala, M. Salmi, K. Alanen, R. Grenman, and S. Jalkanen Vascular Adhesion Protein 1 Mediates Binding of Immunotherapeutic Effector Cells to Tumor Endothelium J. Immunol., June 1, 2001; 166(11): 6937 - 6943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. TOHKA, M.-L. LAUKKANEN, S. JALKANEN, and M. SALMI Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo FASEB J, February 1, 2001; 15(2): 373 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.H. Yu Semicarbazide-sensitive amine oxidase and mortality in chronic heart failure Eur. Heart J., November 2, 2000; 21(22): 1812 - 1814. [PDF]
|
|
|
|
|
|
T. Martelius, M. Salmi, H. Wu, C. Bruggeman, K. Hockerstedt, S. Jalkanen, and I. Lautenschlager Induction of Vascular Adhesion Protein-1 during Liver Allograft Rejection and Concomitant Cytomegalovirus Infection in Rats Am. J. Pathol., October 1, 2000; 157(4): 1229 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kirveskari, P. Bono, K. Granfors, M. Leirisalo-Repo, S. Jalkanen, and M. Salmi Expression of {alpha}4-integrins on human neutrophils J. Leukoc. Biol., August 1, 2000; 68(2): 243 - 250. [Abstract] [Full Text]
|
|
|
|
|
|
J. S. Alexander and D. N. Granger Lymphocyte Trafficking Mediated by Vascular Adhesion Protein-1 : Implications for Immune Targeting and Cardiovascular Disease Circ. Res., June 23, 2000; 86(12): 1190 - 1192. [Full Text] [PDF]
|
|
|
|
|
|
M. Salmi, S. Tohka, and S. Jalkanen Human Vascular Adhesion Protein-1 (VAP-1) Plays a Critical Role in Lymphocyte-Endothelial Cell Adhesion Cascade Under Shear Circ. Res., June 23, 2000; 86(12): 1245 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jaakkola, K. Kaunismaki, S. Tohka, G. Yegutkin, E. Vanttinen, T. Havia, L. J. Pelliniemi, M. Virolainen, S. Jalkanen, and M. Salmi Human Vascular Adhesion Protein-1 in Smooth Muscle Cells Am. J. Pathol., December 1, 1999; 155(6): 1953 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bono, S. Jalkanen, and M. Salmi Mouse Vascular Adhesion Protein 1 Is a Sialoglycoprotein with Enzymatic Activity and Is Induced in Diabetic Insulitis Am. J. Pathol., November 1, 1999; 155(5): 1613 - 1624. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
